Main Menu

Alder BioPharmaceuticals, Inc.

(NASDAQ GS: ALDR)

Summary

Attention investors who purchased shares of Alder BioPharmaceuticals, Inc. before September 16, 2019:

Rigrodsky & Long is investigating potential claims against the board of directors of Alder BioPharmaceuticals, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by H. Lundbeck A/S for approximately $1.5 billion.

Press Release

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Alder BioPharmaceuticals, Inc. (“Alder” or the “Company”) (NASDAQ GS: ALDR) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by H. Lundbeck A/S (“Lundbeck”) in a transaction valued at approximately $1.95 billion. Under the terms of the agreement, shareholders of Alder will receive $18.00 per share in cash, along with one non-tradeable Contingent Value Right (CVR) of $2.00 per share for each share of Alder common stock they own.

If you own common stock of Alder and purchased any shares before September 16, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/offices-contact.  

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Back to Page